Safety and efficacy of doxazosin as an "add-on" antihypertensive therapy in mild to moderate heart failure patients

Roberto Spoladore, Rosa Roccaforte, Gabriele Fragasso, Chiara Gardini, Altin Palloshi, Amarild Cuko, Francesco Arioli, Anna Salerno, Alberto Margonato

Research output: Contribution to journalArticlepeer-review


Objective - Doxazosin treatment has been discouraged in hypertensive patients in order to prevent heart failure (HF) development. However, this drug is still prescribed as an "add-on" medication to achieve a better blood pressure (BP) control. The aim of this study was to evaluate the safety and efficacy of doxazosin as an "add-on" medication in HF patients with uncontrolled hypertension. Methods and results - We reviewed our HF clinic files to collect patient variables recorded at baseline and during follow-up visits in patients receiving, or not, doxazosin. We compared HF-related hospitalization rates and all-cause and cardiovascular mortality rates between patients on doxazosin and those not on doxazosin. We constructed cumulative risk curves for time to first event (HF-related hospitalization and/or death) for both groups of patients. Fifty-two HF patients had been prescribed doxazosin. At baseline, several relevant variables were unevenly distributed between patients receiving doxazosin and those not receiving doxazosin (N = 122), such as left ventricular ejection fraction (LVEF) and NYHA class. HF-related hospitalization and death rates were similar between patients on doxazosin and those not on doxazosin at the end of the follow-up. Even after adjustment for all potentially confounding variables, doxazosin was not associated with HF-related hospitalization and/or death. Doxazosin significantly reduced BP, but did not affect NYHA class. Conclusions - Doxazosin, "on top" of other antihypertensive treatments was safe and effective, and did not appear to be associated with HF-related hospitalization and mortality rates in our patients with mild/moderate HF.

Original languageEnglish
Pages (from-to)485-491
Number of pages7
JournalActa Cardiologica
Issue number4
Publication statusPublished - Aug 2009


  • Antihypertensive therapy
  • Doxazosin
  • Heart failure
  • Prognosis

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'Safety and efficacy of doxazosin as an "add-on" antihypertensive therapy in mild to moderate heart failure patients'. Together they form a unique fingerprint.

Cite this